ClinVar Miner

Submissions for variant NM_033380.3(COL4A5):c.2660G>T (p.Gly887Val)

dbSNP: rs104886201
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV002040361 SCV002307446 likely pathogenic not provided 2020-11-26 criteria provided, single submitter clinical testing In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the triple helix domain of COL4A5. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL4A5, missense variants at these glycine residues are significantly enriched in individuals with disease (PMID: 23720012, 27627812) compared to the general population (ExAC). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL4A5 protein function. This variant has been observed in individual(s) with clinical features of Alport syndrome (PMID: 15954103, Invitae). ClinVar contains an entry for this variant (Variation ID: 24549). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with valine at codon 887 of the COL4A5 protein (p.Gly887Val). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and valine. This variant disrupts the p.Gly887 amino acid residue in COL4A5. Other variant(s) that disrupt this residue have been observed in individuals with COL4A5-related conditions (PMID: 20378821), which suggests that this may be a clinically significant amino acid residue.
GeneDx RCV002040361 SCV002538888 pathogenic not provided 2023-09-13 criteria provided, single submitter clinical testing Reported in a patient with Alport syndrome in published literature (Nagel et al., 2005); clinical information was not provided; Not observed at significant frequency in large population cohorts (gnomAD); Affects a glycine residue in a Gly-X-Y motif in the triple helical region of the COL4A5 gene, where the majority of pathogenic missense variants occur, and is predicted to disrupt normal protein folding and function (HGMD; Jais et al., 2000); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 15954103, 24077912, 10752524)

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.